Limits...
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.

Liepe K, Kropp J, Runge R, Kotzerke J - Br. J. Cancer (2003)

Bottom Line: Mean platelet count decreased from (286+/-75)*10(3) microl(-1) to (215+/-92)*10(3) microl(-1), and mean leucocyte count from (7.7+/-1.5)*10(3) microl(-1) to (6.0+/-1.9)*10(3) microl(-1) in the second to the fourth week after therapy.The maximal differences between the values of platelets and leucocytes before and after therapy were not statistically significant (P=0.021 and 0.094).In conclusion, (188)Re-HEDP is an effective radiopharmaceutical used in the palliative treatment of metastatic bone pain in prostate cancer and shows minimal bone marrow toxicity.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, University Hospital Dresden, Fetscherstr 74, 01307 Dresden, Germany. liepe@rcs.urz.tu-dresden.de

ABSTRACT
Rhenium-188-HEDP ((188)Re-HEDP) is a new and attractive radiopharmaceutical for the treatment of metastatic bone pain. As a product of (188)W/(188)Re generator, it is convenient for clinical therapeutic use with a short physical half-life of 16.9 h and a maximal beta-energy of 2.1 MeV. We investigated the effect of (188)Re-HEDP on pain relief, analgesic intake and impairment of bone marrow function in 27 patients with bone metastases induced from prostate cancer. All patients were interviewed using a standardised set of questions before, and after therapy for 12 weeks. The patients were treated with 2700-3459 MBq of (188)Re-HEDP. Blood samples were taken weekly for 12 weeks, and a blood count was performed. Patients described an improvement on the Karnofsky performance scale from 74+/-7 to 85+/-9% 12 weeks after therapy (P=0.001). The pain score showed a maximum decrease from 44+/-18 to 27+/-20% in the third to the eight week after therapy (P=0.009). Seventy-six percent of the patients described a pain relief without increase of analgesic intake. Twenty percent of the patients could discontinue their analgesics and were pain free. Mean platelet count decreased from (286+/-75)*10(3) microl(-1) to (215+/-92)*10(3) microl(-1), and mean leucocyte count from (7.7+/-1.5)*10(3) microl(-1) to (6.0+/-1.9)*10(3) microl(-1) in the second to the fourth week after therapy. The maximal differences between the values of platelets and leucocytes before and after therapy were not statistically significant (P=0.021 and 0.094). In conclusion, (188)Re-HEDP is an effective radiopharmaceutical used in the palliative treatment of metastatic bone pain in prostate cancer and shows minimal bone marrow toxicity.

Show MeSH

Related in: MedlinePlus

Time course of the Karnofsky performance scale before and within 12 weeks after 188Re-HEDP therapy (with s.d.'s).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376909&req=5

fig1: Time course of the Karnofsky performance scale before and within 12 weeks after 188Re-HEDP therapy (with s.d.'s).

Mentions: In this phase II study, 27 patients with multiple bone metastases from prostate cancer and pain well-controlled by conventional analgesia were included. In previous dose-escalation studies (Palmedo et al, 2000), an activity of 3300 MBq of 188Re-HEDP was determined as suitable for bone pain palliation. We evaluated the effect of 188Re-HEDP on pain relief, reduction of analgesics and changes in quality of life. Before and for 12 weeks after the 188Re-HEDP therapy, weekly interviews with a standardised set of questions concerning pain relief with the visual analogue scale (VAS) from 0 to 100% (Serafini et al, 1998; Kraeber-Bodere et al, 2000), analgesics and Karnofsky performance scale were conducted weekly (Figure 1Figure 1


Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.

Liepe K, Kropp J, Runge R, Kotzerke J - Br. J. Cancer (2003)

Time course of the Karnofsky performance scale before and within 12 weeks after 188Re-HEDP therapy (with s.d.'s).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376909&req=5

fig1: Time course of the Karnofsky performance scale before and within 12 weeks after 188Re-HEDP therapy (with s.d.'s).
Mentions: In this phase II study, 27 patients with multiple bone metastases from prostate cancer and pain well-controlled by conventional analgesia were included. In previous dose-escalation studies (Palmedo et al, 2000), an activity of 3300 MBq of 188Re-HEDP was determined as suitable for bone pain palliation. We evaluated the effect of 188Re-HEDP on pain relief, reduction of analgesics and changes in quality of life. Before and for 12 weeks after the 188Re-HEDP therapy, weekly interviews with a standardised set of questions concerning pain relief with the visual analogue scale (VAS) from 0 to 100% (Serafini et al, 1998; Kraeber-Bodere et al, 2000), analgesics and Karnofsky performance scale were conducted weekly (Figure 1Figure 1

Bottom Line: Mean platelet count decreased from (286+/-75)*10(3) microl(-1) to (215+/-92)*10(3) microl(-1), and mean leucocyte count from (7.7+/-1.5)*10(3) microl(-1) to (6.0+/-1.9)*10(3) microl(-1) in the second to the fourth week after therapy.The maximal differences between the values of platelets and leucocytes before and after therapy were not statistically significant (P=0.021 and 0.094).In conclusion, (188)Re-HEDP is an effective radiopharmaceutical used in the palliative treatment of metastatic bone pain in prostate cancer and shows minimal bone marrow toxicity.

View Article: PubMed Central - PubMed

Affiliation: Department of Nuclear Medicine, University Hospital Dresden, Fetscherstr 74, 01307 Dresden, Germany. liepe@rcs.urz.tu-dresden.de

ABSTRACT
Rhenium-188-HEDP ((188)Re-HEDP) is a new and attractive radiopharmaceutical for the treatment of metastatic bone pain. As a product of (188)W/(188)Re generator, it is convenient for clinical therapeutic use with a short physical half-life of 16.9 h and a maximal beta-energy of 2.1 MeV. We investigated the effect of (188)Re-HEDP on pain relief, analgesic intake and impairment of bone marrow function in 27 patients with bone metastases induced from prostate cancer. All patients were interviewed using a standardised set of questions before, and after therapy for 12 weeks. The patients were treated with 2700-3459 MBq of (188)Re-HEDP. Blood samples were taken weekly for 12 weeks, and a blood count was performed. Patients described an improvement on the Karnofsky performance scale from 74+/-7 to 85+/-9% 12 weeks after therapy (P=0.001). The pain score showed a maximum decrease from 44+/-18 to 27+/-20% in the third to the eight week after therapy (P=0.009). Seventy-six percent of the patients described a pain relief without increase of analgesic intake. Twenty percent of the patients could discontinue their analgesics and were pain free. Mean platelet count decreased from (286+/-75)*10(3) microl(-1) to (215+/-92)*10(3) microl(-1), and mean leucocyte count from (7.7+/-1.5)*10(3) microl(-1) to (6.0+/-1.9)*10(3) microl(-1) in the second to the fourth week after therapy. The maximal differences between the values of platelets and leucocytes before and after therapy were not statistically significant (P=0.021 and 0.094). In conclusion, (188)Re-HEDP is an effective radiopharmaceutical used in the palliative treatment of metastatic bone pain in prostate cancer and shows minimal bone marrow toxicity.

Show MeSH
Related in: MedlinePlus